Therefore, it is highly desirable to find more efficacious UGT1A1 inducers as novel anti-hyperbilirubinaemia agents for the treatment of UGT1A1-associated human diseases and drug-induced liver toxicity (Aoshima et al., 2014; Gong et al., 2014; Zeng et al., 2016). The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.